LEGEND BIOTECH CORP-ADR (LEGN)

US52490G1022 - ADR

56.09  -0.84 (-1.48%)

After market: 56.09 0 (0%)

News Image
a month ago - Seeking Alpha

Legend Biotech stock rises after EU backs label expansion for multiple myeloma therapy

Legend Biotech shares surge as EU drug regulator panel recommends label expansion for Carvykti in multiple myeloma patients.

News Image
a month ago - Seeking Alpha

J&J wins EU backing to expand labeling of CAR-T therapy (NYSE:JNJ)

Johnson & Johnson(JNJ) wins endorsement in Europe to expand labeling for its CAR-T therapy Carvykti marketed with Legend Biotech (LEGN). Read more here.

News Image
3 months ago - Seeking Alpha

Legend Biotech, J&J's Carvykti drug gets label update (NASDAQ:LEGN)

Legend Biotech (LEGN) and J&J's (JNJ) multiple myeloma treatment Carvykti get label update to include a warning on blood cancer. Read more here.

News Image
3 months ago - Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Legend Biotech Corporation - LEGN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Legend Biotech Corporation ("Legend" or the "Company") (NASDAQ: LEGN). Such...

News Image
4 months ago - Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Legend Biotech Corporation - LEGN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Legend Biotech Corporation ("Legend" or the "Company") (NASDAQ: LEGN). Such...

News Image
4 months ago - Seeking Alpha

FDA probing serious risk of T-cell malignancies in CAR-T cell therapy patients

The FDA on Tuesday said it was looking into reports of T-cell malignancies in patients who have been treated with CAR-T cell immunotherapies. Read more here.

News Image
4 months ago - Seeking Alpha

FDA investigating serious risk of T-cell malignancies in CAR-T cell therapy patients

The FDA on Tuesday said it was looking into reports of T-cell malignancies in patients who have been treated with CAR-T cell immunotherapies. Read more here.

News Image
4 months ago - Market News Video

Legend Biotech is Now Oversold (LEGN)

News Image
4 months ago - Seeking Alpha

Legend Biotech GAAP EPS of -$0.17 beats by $0.14, revenue of $96.01M misses by $3.5M (NASDAQ:LEGN)

Legend Biotech reports Q3 2023 results with a beat in GAAP EPS but miss in revenue, reflecting a 250.9% YoY growth and a -$0.17 EPS, respectively.

News Image
4 months ago - Market News Video

LEGN Crosses Below Key Moving Average Level

News Image
4 months ago - The Motley Fool

Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On

Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector.